An informed capability assessment of different geographies, such as North America, Europe and Asia Pacific, is based on a variety of relevant parameters, such as number of CMOs, number of clinical sites, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of CMOs offering manufacturing for API / FDF, number of CMOs having capabilities for clinical / commercial manufacturing, current demand for peptide therapeutics and installed manufacturing capacity in a particular region. Where, North America emerged as the most prominent region as per the above-mentioned parameters. It is worth highlighting that across all the regions, the peptide manufacturing facilities are capable of providing manufacturing services at the clinical scale.
The figure presents the analytical distribution of the above-mentioned parameters in North America.
Global Peptide Therapeutics Market is predicted to reach USD 48.04 billion by 2025 owing to rise in demand for efficient & speedy treatment of cancer and other lifestyle-related disorders.
Peptides are highly modifiable and versatile in comparison to other drugs, which make them highly profitable to sponsors.
Due to their feature of versatility, they are used in multiple medical conditions that leads to higher penetration of peptide therapeutics industry.
Apart from therapeutics effects, the market is also gaining attraction due to comparatively easy marketing approval and familiarity.Download Sample Report @ https://www.millioninsights.com/industry-reports/peptide-therapeutics-market/request-sampleAlong with the growing prevalence of cardiovascular disorders and cancers, the increasing research & development activities and rich peptide therapeutics pipeline are predicted to support the growth of the market in near future.
Advanced research & development facilities and new peptide developments by pharma companies are driving the demand for reasonably priced peptide therapeutics.Nevertheless, the large scale production of peptide with increasing complexities of peptides is a major challenge for peptide therapeutics market.
The development of multifunctional peptides and rise in number of collaboration for the progress of peptide conjugates are currently ruling the market.Latest advances in peptide synthesis technology is projected to be the key driver for the growth of peptide therapeutics industry.
Initially, the development of peptides as therapeutic agents was avoided by the pharmaceutical industry due to their low stability, rate of degradation and poor delivery.
However, in the present times, with increasing amounts of economic resources being diverted to healthcare R, new avenues have opened up for peptide therapeutics.
Increasing healthcare expenditure and increasing FDI in emerging economies along with the emergence of prominent pharmaceutical and biotech companies is fuelling market growth in peptide therapeutics.
However, various factors such as increasing cost of developing peptides, rapid metabolism of peptide drugs and a stringent regulatory framework may restrain the growth of therapeutic peptides.
Read Report Summary: https://www.factmr.com/report/191/peptide-based-cardiovascular-therapeutics-marketThe global peptide based cardiovascular therapeutics market is slated to touch a value of nearly US$ 1,960 Mn in the year 2022 and grow at a robust CAGR during the assessment period.As per the forecast of Fact.MR, the eptifibatide segment is slated to touch a value of nearly US$ 600 Mn in the year 2022.
The eptifibatide segment is estimated to account for nearly one-third of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.To get Intensive Insights: https://www.factmr.com/connectus/sample?flag=RM_id=191As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 425 Mn in the year 2017.